<DOC>
	<DOCNO>NCT00603460</DOCNO>
	<brief_summary>Subjects recurrent epithelial ovarian carcinoma primary peritoneal cancer , previously undergone vaccination clinical study UPCC-11807 DCVax-L , autologous vaccine DC load vitro autologous tumor lysate . Phase I Subjects enrol study receive leukapheresis ; follow cyclophosphamide/fludarabine-induced lymphodepletion ; follow adoptive transfer ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cell ; follow single DCVax-L vaccination , establish feasibility safety approach . Primary Objectives Phase I To determine feasibility safety administer vaccine-primed , ex vivo CD3/CD28-costimulated autologous peripheral blood T cell combination DCVax-L vaccination , follow lymphodepletion high dose cyclophosphamide/fludarabine . Phase II Twenty-two additional subject randomize receive either : - ARM-IIA : maintenance DCVax-L vaccination , combination oral metronomic cyclophosphamide , - ARM-IIB : leukapheresis , follow cyclophosphamide/fludarabine-induced lymphodepletion , follow adoptive transfer ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cell , follow maintenance DCVax-L vaccination , plus oral metronomic cyclophosphamide . Primary Objective Phase II To assess distribution progression-free survival 6 month patient treat maintenance DCVax-L vaccination plus oral metronomic cyclophosphamide well patient treat ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cell lymphodepletion high dose cyclophosphamide / fludarabine , follow DCVax-L boost vaccination metronomic oral cyclophosphamide .</brief_summary>
	<brief_title>DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells Recurrent Ovarian Primary Peritoneal Cancer</brief_title>
	<detailed_description>Description treatment Phase I : - Patients offer , medically indicate , tumor resection needle aspiration malignant effusion order make additional dos DCVax-L vaccine . - If subject receive DCVax-L vaccination within last 3-4 week , DCVax-L available , subject option receive one dose DCVax-L enrolment , boost frequency vaccine-primed T cell . - Subjects receive single course outpatient lymphodepleting chemotherapy intravenous cyclophosphamide ( 300 mg/m2/d 3 day ) intravenous fludarabine ( 30 mg/m2/d 3 day ) administer day 8 10 . - Ex vivo CD3/CD28-costimulated lymphocyte infuse ~2 day last day fludarabine infusion . - Patients receive DCVax-L vaccine ~24-48 hr T cell infusion . - Subjects contact every 6 month 5 year survival . Description treatment Phase II : In ARM-IIA : - Patients offer , medically indicate , tumor resection needle aspiration malignant effusion order make additional dos DCVax-L vaccine . - Subjects receive intradermal vaccination DCVax-L every 8 week , four cycle total . The first vaccine administer day 0 , sooner 4 week previous DCVax-L vaccination relate clinical study UPCC-11807 . - Subjects receive oral cyclophosphamide metronomic schedule dose ( 50 mg daily ) every week , start ~3 week DCVax-L every vaccine cycle . - Patients offer ( right refuse ) CT-guided needle biopsy needle aspiration malignant effusion second vaccine . In ARM-IIB : - Patients offer , medically indicate , tumor resection needle aspiration malignant effusion order make additional dos DCVax-L vaccine . - Subjects undergo ~10-15 liter leukapheresis derive vaccine-primed peripheral blood lymphocyte ( PBL ) day 0 . The apheresis material transfer Cell Vaccine Facility University Pennsylvania ( Penn CVPF ) T cell manufacturing . - If subject receive DCVax-L vaccination within last 3-4 week , DCVax-L available , subject option receive one dose DCVax-L enrolment , boost frequency vaccine-primed T cell . - Subjects receive single course outpatient lymphodepleting chemotherapy intravenous cyclophosphamide ( 300 mg/m2/d 3 day ) intravenous fludarabine ( 30 mg/m2/d 3 day ) . - Ex vivo CD3/CD28-costimulated lymphocyte infuse ~2 day last day fludarabine infusion . - Patients receive DCVax-L vaccine boost every 8 week total four vaccine . The first DCVax-L give ~24-48 hr T cell infusion . - Following DCVax-L , subject receive oral cyclophosphamide metronomic schedule dose ( 50 mg daily ) every week x 3 cycle , start ~3 week DCVax-L every vaccine cycle . - Patients offer ( right refuse ) CT-guided needle biopsy needle aspiration malignant effusion ~1-2 week second vaccine</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Previous participation UPCC 11807 ( A Phase I Clinical Trial Autologous Dendritic Cell Vaccine Loaded Autologous Tumor Cell Lysate Recurrent Ovarian Primary Peritoneal Cancer ) PS &lt; 2 Subject must tumor lysate sufficient prepare least 4 DCVaxL vaccine 18 year age old Life expectancy &gt; 4 month Signed Informed Consent Normal organ bone marrow function define : ANC ≥ 1,000/μl Platelets &gt; 100,000/μl AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional upper limit normal Bilirubin &lt; 2.0 mg/dL unless secondary bile duct blockage tumor Creatinine &lt; 1.5 X upper limit normal Subjects follow : know brain metastasis renal insufficiency liver failure organ allograft know autoimmune/collagen vascular disorder pregnant breast feed nonhealing wound , ulcer , bone fracture positive serum antiYo ( cdr2 ) antibodies uncontrolled hypertension Myocardial infarction unstable angina within 6 month prior registration New York Heart Association ( NYHA ) Grade II great congestive heart failure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
</DOC>